A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, Randomized, Open-Label, Parallel, Comparative, Dose-Response Study to
Evaluate the Efficacy and Safety study of KRN321 of subcutaneous injection in Adult Subjects
with Low- or Intermediate-1-Risk Myelodysplastic Syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.